You are here
ProQinase is a research division of KTB Tumorforschungs GmbH, a research company that is part of the privately held Tumour Biology Centre Freiburg, Germany and has CRO status. ProQinase (KTB) was established in 2001 and currently employs 33 staff members including 12 PhD scientists. Worldwide commercialisation of products and services of ProQinase is performed by the marketing unit ProQinase GmbH, a wholly owned subsidiary of KTB Tumorforschungs GmbH.
ProQinase (KTB) serves as CRO for most of the major pharmaceutical companies. Main area of expertise is biochemical, cellular and in vivo characterisation and development of drug candidates in cancer, as well as the development of novel oncological assay systems. ProQinase (KTB)´s biochemical platform comprises production of and assays for hundreds of kinases used for robot-based HTS activity screening in-house. ProQinase (KTB)´s cellular platform encompasses various medium-throughput cellular assay services to measure impact of compounds on kinase activity and cancer related phenotypes. ProQinase (KTB) has established a series of 3D cellular assays designed to measure the effect of anti-cancer drugs on transformation and angiogenesis both in vitro and in vivo. ProQinase (KTB) successfully integrates these platforms for preclinical drug development which led e.g. to 4SC-203, an anti-AML FLT3-kinase inhibitor which was co-developed with 4SC AG and has passed clinical phase I recently.
SyStemAge consortium partner from Jan 2013 - May 2015.